Allergic Rhinitis Treatment with Montelukast and Loratadine

Mechanism of Action and Efficacy

The American Academy of Allergy, Asthma, and Immunology recommends loratadine, a second-generation antihistamine, for typical allergic rhinitis symptoms like sneezing, itching, and rhinorrhea, as it blocks peripheral histamine H1-receptors with high selectivity, preventing histamine-mediated allergic symptoms 1, 2
Montelukast, a leukotriene receptor antagonist, blocks leukotriene receptors, targeting a different inflammatory pathway than histamine, and addresses the inflammatory cascade rather than just histamine-mediated symptoms 2

Loratadine and montelukast show no significant difference in efficacy when compared head-to-head for allergic rhinitis symptoms, but both are less effective than intranasal corticosteroids as monotherapy 2, 3
The combination of an antihistamine (like loratadine) plus a leukotriene antagonist (like montelukast) may provide broader symptom coverage and have an additive effect, though not all studies confirm this benefit 2

Loratadine does not cause sedation at recommended doses (10mg daily) and is truly non-sedating, making it a preferred option when sedation must be absolutely avoided 1, 4, 5
Montelukast has an excellent safety profile with minimal sedative effects and is approved for use down to 6 months of age 2
Patients with coexisting asthma and allergic rhinitis may benefit from montelukast, as it is approved for both conditions and may be more practical 2

Second-generation antihistamines like loratadine have been shown to be well-tolerated with very good safety profiles in young children, and montelukast is approved down to 6 months of age 2, 3, 6
It is essential not to assume montelukast is superior to loratadine, as they have equivalent efficacy for allergic rhinitis symptoms, and not to use either as monotherapy when intranasal corticosteroids would be more appropriate 2, 3